# Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

> **NCT01438424** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1053 (actual)

## Conditions studied

- Hepatitis B Virus
- HBV

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT01438424
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2009-12
- **Final completion:** 2011-04
- **Target enrollment:** 1053 (ACTUAL)
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01438424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01438424, "Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01438424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*